{"brief_title": "Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)", "brief_summary": "This study will determine the safety and effectiveness of AMG 706 in patients with advanced GIST.", "detailed_description": "Expanded Access: Amgen provides expanded access for this clinical trial. Contact the Amgen Call Center (866-572-6436) for more information.", "condition": "Gastrointestinal Cancer", "intervention_type": "Drug", "intervention_name": "AMG 706", "description": "AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.", "arm_group_label": "Arm", "criteria": "Inclusion Criteria - Age \u2265 18 years; - Disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) during previous treatment with imatinib mesylate at least 600 mg daily for at least 8 weeks, as per two independently assessed prestudy computerized tomography (CT) scans; - Presence of at least one measurable (per RECIST) - Progressing tumor lesion not previously treated with radiotherapy or embolization and evaluable by CT scan or magnetic resonance imaging (MRI); - Karnofsky performance status \u2265 60; - imatinib treatment terminated at least 7 days before study day 1; - Adequate hepatic, renal, and cardiac function. Exclusion criteria: - Prior malignancy (other than GIST, in situ cervical cancer, or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for \u2265 3 years; cardiac disease including myocardial infarction, unstable angina, and congestive heart failure (New York Heart Association class > II), - uncontrolled hypertension (systolic > 145 mmHg or diastolic > 85 mmHg), - History of arterial thrombosis or deep vein thrombosis (including pulmonary embolus) within 1 year of study day 1; - Absolute neutrophil count < 1.5x109/L, platelet count < 100x109/L, hemoglobin < 9.0 g/dL; - Prior treatment with motesanib diphosphate or other KIT (except imatinib) or VEGF inhibitors. - The study was approved by the institutional review board of each participating institution, and all patients provided written informed consent before any study-related procedures were performed.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00089960.xml"}